MedTrace Logo

Lipoic Acid and Prevention of Heart Disease

NCT00765310 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 81

Last updated 2025-04-11

No results posted yet for this study

Summary

The purpose of this study is to see if a dietary supplement, R-alpha lipoic acid, is able to reduce risk factors such as body weight and high blood cholesterol levels in overweight or obese participants.

Conditions

Interventions

DIETARY_SUPPLEMENT

R-alpha lipoic acid

600 mg in morning on empty stomach (two 300 mg capsules)

DIETARY_SUPPLEMENT

Placebo

two capsules once daily in morning on empty stomach

Sponsors & Collaborators

  • Oregon Health and Science University

    collaborator OTHER

  • National Center for Complementary and Integrative Health (NCCIH)

    collaborator NIH

  • Oregon State University

    lead OTHER

Principal Investigators

  • Gerd Bobe, PhD · Oregon State University

  • Jonathan Q Purnell, MD · Oregon Health and Science University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-04-01
Primary Completion
2011-11-01
Completion
2024-10-01

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00765310 on ClinicalTrials.gov